Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Neuraxis (NRXS) Research & Development (2022 - 2025)

Neuraxis' Research & Development history spans 4 years, with the latest figure at $1515.0 for Q3 2025.

  • For Q3 2025, Research & Development fell 98.8% year-over-year to $1515.0; the TTM value through Sep 2025 reached $27844.0, down 84.86%, while the annual FY2024 figure was $206107.0, 21.73% up from the prior year.
  • Research & Development for Q3 2025 was $1515.0 at Neuraxis, up from -$54205.0 in the prior quarter.
  • Across five years, Research & Development topped out at $126247.0 in Q3 2024 and bottomed at -$54205.0 in Q2 2025.
  • The 4-year median for Research & Development is $19978.0 (2024), against an average of $37163.7.
  • The largest annual shift saw Research & Development skyrocketed 999.5% in 2024 before it plummeted 199.8% in 2025.
  • A 4-year view of Research & Development shows it stood at $86175.0 in 2022, then plummeted by 102.58% to -$2221.0 in 2023, then surged by 999.5% to $19978.0 in 2024, then crashed by 92.42% to $1515.0 in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Research & Development are $1515.0 (Q3 2025), -$54205.0 (Q2 2025), and $60556.0 (Q1 2025).